Nothing Special   »   [go: up one dir, main page]

WO1996021701A2 - Wear resistant image printing on latex surfaces - Google Patents

Wear resistant image printing on latex surfaces Download PDF

Info

Publication number
WO1996021701A2
WO1996021701A2 PCT/US1996/000163 US9600163W WO9621701A2 WO 1996021701 A2 WO1996021701 A2 WO 1996021701A2 US 9600163 W US9600163 W US 9600163W WO 9621701 A2 WO9621701 A2 WO 9621701A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
rubber
ink
aromatic hydrocarbon
Prior art date
Application number
PCT/US1996/000163
Other languages
English (en)
French (fr)
Other versions
WO1996021701A3 (en
Inventor
Henry Mattesky
James Gugger
Original Assignee
Magla International Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magla International Ltd. filed Critical Magla International Ltd.
Priority to JP8521749A priority Critical patent/JPH11501337A/ja
Priority to EP96902610A priority patent/EP0802953A2/en
Priority to US08/875,414 priority patent/US5854306A/en
Priority to BR9606896A priority patent/BR9606896A/pt
Priority to EA199700099A priority patent/EA000164B1/ru
Priority to AU46949/96A priority patent/AU703440B2/en
Publication of WO1996021701A2 publication Critical patent/WO1996021701A2/en
Publication of WO1996021701A3 publication Critical patent/WO1996021701A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00Inks
    • C09D11/02Printing inks
    • C09D11/10Printing inks based on artificial resins
    • C09D11/106Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B41PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41MPRINTING, DUPLICATING, MARKING, OR COPYING PROCESSES; COLOUR PRINTING
    • B41M1/00Inking and printing with a printer's forme
    • B41M1/26Printing on other surfaces than ordinary paper
    • B41M1/32Printing on other surfaces than ordinary paper on rubber

Definitions

  • a method for printing images on a latex rubber surface which comprises applying an ink containing natural or synthetic rubber, pigment dispersion, and a solvent medium in particular an aromatically unsaturated solvent medium for said rubber.
  • the ink may additionally comprise an aryl diisocyanate.
  • the aryl diisocyanate may be either in the base coat or the ink.
  • a base coat of natural rubber in such a solvent is required, where the rubber in the ink is synthetic rubber.
  • the aryl diisocyanate may be either in the base coat or the ink.
  • a portion of the solvent may be replaced by a terpene, a terpenoid or a high boiling ketone suitably having a boiling point over 120°C, such as isophorone or the like.
  • the efficacy of the printing may be improved by certain pre- and post- printing steps.
  • One such additional step is heating the printing surface.
  • Another, highly desirable, added step is placing a base coat upon the printing surface that receives the image.
  • this base coat is allowed to dry to tackiness before the image is printed.
  • this base coat comprises natural rubber in an aromatically unsaturated solvent.
  • a critical feature of the invention is the presence of an agent capable upon cure, of forming a chemically and abrasion resistant, tough flexible structure integrating the rubber of said base coat, where it is present, the rubber of the ink , together with the pigment therein, and the rubber of the latex surface, in at least one of the base coat and the ink.
  • an agent capable upon cure of forming a chemically and abrasion resistant, tough flexible structure integrating the rubber of said base coat, where it is present, the rubber of the ink , together with the pigment therein, and the rubber of the latex surface, in at least one of the base coat and the ink.
  • an agent is an aryl diisocyanate.
  • the integrating agent may be in either the ink phase and/or the base coat.
  • the ink as well as the base coat may be applied using a number of common printing techniques including: gravure printing, flexo printing, screen printing, and pad printing.
  • Pad printing howeverl has been found to be superior for the inventive purposes, such as: printing individual rubber articles like rubber gloves.
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS There is provided a method and a formulation for printing images on latex rubber surfaces. It is desirable that the weight amount of the aryl diisocyanate is between 0.5 and 3.0 times that of the total rubber in solution within the ink or within the base coat where used or both.
  • the rubber may be natural rubber or synthetic rubber.
  • the diisocyanate is selected from the group consisting of toluene -, methylene diphenyl- and polymeric methylene diphenyl diisocyanates, and mixtures thereof.
  • the rubber in the ink may be natural rubber or synthetic rubber such as neoprene rubber or blends thereof.
  • the ink at printing time, should have a viscosity at 20°C of between 800 and 3000 cps.
  • the use of synthetic rubber in the ink is preferred over natural rubber since its chemical resistance is greater.
  • natural rubber when mixed with aryl diisocyanate will provide sufficient resistivity.
  • Aryl diisocyanate when cured per se will form a hard brittle product, In the presence of rubber, it becomes integrated therewith to yield a flexible, tough, and chemically resistant structure or matrix, that provides the unique printing product associated with this invention.
  • Inks containing the diisocyanate should be promptly used after mixing, suitably within 10 hours of preparation.
  • Prior art printing solvents generally use mineral spirits, such as: aliphatic or alicyclic hydrocarbons.
  • the solvents used in the inks and precoat of the invention are aromatically, unsaturated solvents.
  • Aliphatic esters of aromatic acids, or higher liquid aromatic hydrocarbons are preferred.
  • methyl naphthalene is preferred.
  • the latter may, under certain conditions, be partially replaced with terpenes, or terpenoids, such as: dilimonene, or high boiling ketones, such as: isophorone.
  • the methyl naphthalene is preferred.
  • Glidsol 90 manufactured by SCM Glisol Organics, 210 Summit Ave., Montvale NJ 07645, is a terpene formulation that is especially preferred.
  • Terpenes and terpenoids can be used in the base coat, but this is not preferred. It should be noted, that commercial methyl naphthalene, is in fact, a complex mixture containing dimethyl naphthalene, ethyl methyl naphthalene, and other heavy, fractional coal tar components.
  • the actual amounts of rubber, solvents, and pigments used in the printing formulations of this invention may vary quite substantially depending on the desired consistency and drying speed.
  • the desired ink viscosity range at 20°C, is approximately between 800 and 3,000 cps. Approximately between 5 and 40 wt% of pigment is contained in the ink composition.
  • the image to be printed on a latex rubber surface in accordance with the ink formulation of this invention is not particularly dependent upon any conventional printing method. Stability of the image is improved by the additional step of heating the printed surface. Suitably, the heating is accomplished in a temperature range of from approximately 95 to 130°C. for 10 to 20 minutes, or approximately from 190 to 230°C. for 3 to 8 seconds.
  • Heat curing can increase the chemical and abrasive resistance of the printed ink image to the commonly used, household cleaner, Pine Sol ® .
  • a simple test of ink image endurance is to rub the printed image with a pad impregnated with Pine Sol at recommended, household detergent strength.
  • Resistance of Neoprene, and natural rubber-containing inks of this invention are capable of withstanding 35 to 100 rubs. This is achievable with the inventive ink formulations due to the presence of the aryl diisocyanate, which as aforementioned, intimately embeds within the rubber molecules.
  • the resistance of the printed image may also be improved by certain pre-, and post-printing steps.
  • washing the surface of the article with water and surfactant, followed by drying; or just washing the surface with a hydrocarbon solvent, will improve the printing process.
  • the washing procedure is not recommended for gloves containing flock on their inner surfaces. Heating the printed image for approximately 3 to 6 seconds at approximately between 190-220°C, is helpful.
  • One of the unusual, and totally unexpected aspects of this invention is the ability of the printed image product to become increasingly resistant to chemical attack and abrasion with time. It has been observed that while the printed image product is contact stable immediately after the initial heating step, the resistance to chemical abrasion continues to build towards a maximum over an extended period at ambient temperature. Testing reveals that the printed image product reaches maximum efficacy between 20 and 60 days after printing. This slow cure does not pose a marketing problem, however, because the mean time between manufacture and the arrival at the point of sale of a typical printed latex rubber glove, is usually about 75 days.
  • Printed image stability is also improved by placing a base coat upon the surface receiving the printed image.
  • the base coat is applied and allowed to dry until tacky.
  • the image is then printed upon the tacky base coat surface.
  • the base coat can comprise natural rubber in an aromatically unsaturated solvent.
  • this base coat also contains an aryl diisocyanate, in an approximate weight amount of between 0.5 and 3.0 times that of the rubber in solution.
  • One method of printing an image on a latex rubber surface includes preparing a clear base coat solution, comprising natural rubber of approximately one to ten parts by weight in an aromatic hydrocarbon solvent of approximately 45 to 50 parts by weight.
  • This clear base coat solution is then admixtured with a premixed moiety comprising an aromatic hydrocarbon solvent of approximately between 2 to 15 parts by weight containing an aryl diisocyanate of approximately 1 to 30 parts by weight.
  • the above admixture is then mixed with a pigment having an approximate weight of between 0.3 to 5.0 times that of the rubber in solution.
  • the components of this formulation, viz., the clear coat, the premix, and the pigment are mixed at ambient temperature, and then printed upon the latex rubber surface preferably within 10 hours of the mixing.
  • a generally preferred method of printing an image on a latex rubber surface comprises the step of applying a base coat to the rubber surface containing natural rubber in approximate range by weight of between 5 to 15 parts in a solvent approximately ranging in weight between 80 to 120 parts, and an aryl diisocyanate ranging in weight between 0 to 45 parts.
  • the image is then printed onto the base coat utilizing an ink whose formulation comprises natural or synthetic rubber in approximately 1 to 10 parts by weight; a rubber solvent in the approximate weight of between 30 to 60 parts; a pigment of approximately 0.3 to 5.0 times the weight of the rubber; and an aryl diisocyanate in the weight range of approximately 0 to 30 parts.
  • the rubber solvent in the aforesaid formulation can be an aromatic hydrocarbon, a terpene, a terpenoid, a ketone boiling above 120°C, or a mixture thereof.
  • the rubber solvent in the base coat may be an aromatic hydrocarbon solvent comprising approximately 60 to 90 parts by weight, a terpene, or terpenoid solvent in approximate weight of between 0 to 60 parts.
  • the rubber solvent in the ink may be an aromatic hydrocarbon solvent comprising approximately 30 to 50 parts by weight, and a terpene or terpenoid solvent of approximately 0 to 30 parts by weight.
  • Various combinations of base coat and ink compositions are within the scope of the present invention.
  • the ink comprises synthetic rubber in approximately 1 to 10 parts by weight; an aromatic hydrocarbon solvent in about 30 to 80 parts by weight; and a pigment that is 0.3 to 5 parts by weight.
  • the base coat can comprise natural rubber in approximate weight of between 5 to 15 parts; an aromatic hydrocarbon solvent in approximately 80 to 120 parts by weight; and an aryl diisocyanate in approximate weight of between 1 to 45 parts.
  • the ink comprises synthetic rubber in approximate weight of between 1 to 10 parts; an aromatic hydrocarbon solvent of approximately 30 to 60 parts by weight; a pigment in approximate weight of between 0.3 to 5.0 parts; and an aryl diisocyanate approximately 1 to 30 parts by weight.
  • the base coat can comprise natural rubber approximately 5 to 15 parts by weight in an aromatic hydrocarbon solvent comprising approximately 80 to 120 parts by weight.
  • the ink comprises synthetic rubber in about 1 to 10 parts by weight; an aromatic hydrocarbon solvent approximately 15 to 60 parts by weight; a terpene, or terpenoid solvent in approximate weight range of 5 to 40 parts; and a pigment approximately 0.3 to 5.0 parts by weight.
  • the base coat comprises natural rubber approximately between 5 to 15 parts by weight; an aromatic hydrocarbon solvent in an approximate weight range of between 80 to 120 parts; and an aryl diisocyanate of about 1 to 45 parts by weight.
  • the ink comprises synthetic rubber in approximate weight range of 1 to 10 parts; an aromatic hydrocarbon solvent of about 15 to 60 parts by weight; a terpene, or terpenoid solvent of approximately 5 to 40 parts by weight; a pigment in a weight range of between 0.3 to 5.0 parts, and an aryl diisocyanate in approximate weight of between 1 to 30 parts.
  • the base coat comprises natural rubber from approximately 5 to 15 parts by weight in an aromatic hydrocarbon solvent of about 80 to 90 parts by weight.
  • aromatic hydrocarbon of choice in the above formulations is commercial grade methyl naphthalene.
  • a series of printing stations each comprise pad printer.
  • the printing stations are aligned to provide sequential processing.
  • a first printing station is charged with the base coat, and the pigmented printing ink is charged to the second printing station.
  • a number of colors may be printed by placing additional pad printing stations in line all subsequent to the first base coat printer. It has been found that improved results are obtained by not allowing the base coat to thoroughly dry before the pigmented ink is applied .
  • a slight base coat tackiness should remain as the rubber glove passes under subsequent print stations.
  • Heat is applied to the print surface by contact heating with a teflon coated aluminum plated heater to an approximate temperature of 215°C. for five seconds. The heating procedure assists in the cure of the printing ink, which effects its ability to resist chemical attack and abrasion.
  • DABCO T-12 (Dibutyltin Dilaurate): Air Products & Chemicals Inc.
  • PAPI 2021 polymethylene polyphenyl isocyanate mfg. by Dow Chemical Company, Plastics Div., Midland Ml.
  • Di-XXXX Pigments 25% Pigment, 75% Dinonyl Phthalate; Mfg by Cardinal
  • NEOPRENE GW Dupont Co., Elastomer Div., Wilmington DE
  • Example I A printing ink is prepared as follows:
  • Agerite Stalite 0.34 Total 120 An image was imprinted upon a latex surface using the above formulation. The aforementioned rubbing test was performed using pads impregnated with Pine Sol ® . The test was conducted 12 days after printing.
  • the printed image was air cured. Only one rub was required to remove the image.
  • Example II In the ink formulation given in Example I, 17 parts of PAPI 2020 were added to the ink. After printing an image upon a latex surface, a Pine sol ® test was performed after 12 days. The printed image was air cured at ambient. It required 6 rubs to erase the image.
  • Example III A base coat is prepared as follows: PARTS *
  • Example II The above base coat was applied to a natural rubber surface just prior to application of the ink shown in Example II.
  • a Pine sol ® rubbing test was performed after 12 days. It took approximately between 12 to 22 rubs to remove the printed image. This test was additionally performed using a cure of 60 days. The image required 40 rubs for removal.
  • Example IV Natural rubber ink To the composition of Example III was added PAPI 2020 8 parts Blue Di-61 12 20 parts The Pine sol ® rubbing Test was performed after the printed image was allowed to cure for 9 days. The image was removed after 16 rubs.
  • Example V An ink of Example IV was applied over a base coat of Example II.
  • PAPI 2020 (Premix) 0.5 3.0 15.0
  • PAPI 2020 (Premix) ... 0.5 3.0 1 5.0
  • Curing Time was 60 days.
  • a rubbing Pine sol ® test required 40 rubs to remove the printed image.
  • Example X
  • PAPI 2020 (Premix) 1.0 6.0 12.0
  • Neoprene-PAPI 2020 8.85:1.0 1 .42:1.0 0.71 :1 .0

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Printing Methods (AREA)
  • Paints Or Removers (AREA)
PCT/US1996/000163 1995-01-09 1996-01-05 Wear resistant image printing on latex surfaces WO1996021701A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP8521749A JPH11501337A (ja) 1995-01-09 1996-01-05 ラテックス表面における耐磨耗性イメージ印刷
EP96902610A EP0802953A2 (en) 1995-01-09 1996-01-05 Wear resistant image printing on latex surfaces
US08/875,414 US5854306A (en) 1996-01-05 1996-01-05 Wear resistant image printing on latex surfaces
BR9606896A BR9606896A (pt) 1995-01-09 1996-01-05 Impressão de imagem resistente á água em superficies de látex
EA199700099A EA000164B1 (ru) 1995-01-09 1996-01-05 Состав для печати изображения на поверхности изделия из каучукового латекса, способ печати изображения и изделия из каучукового латекса
AU46949/96A AU703440B2 (en) 1995-01-09 1996-01-05 Wear resistant image printing on latex surfaces

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37002495A 1995-01-09 1995-01-09
US08/370,024 1995-01-09

Publications (2)

Publication Number Publication Date
WO1996021701A2 true WO1996021701A2 (en) 1996-07-18
WO1996021701A3 WO1996021701A3 (en) 1996-09-12

Family

ID=23457914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000163 WO1996021701A2 (en) 1995-01-09 1996-01-05 Wear resistant image printing on latex surfaces

Country Status (12)

Country Link
EP (1) EP0802953A2 (pt)
JP (1) JPH11501337A (pt)
CN (1) CN1176652A (pt)
AR (1) AR000644A1 (pt)
AU (1) AU703440B2 (pt)
BR (1) BR9606896A (pt)
CA (1) CA2211017A1 (pt)
EA (1) EA000164B1 (pt)
IL (1) IL116690A (pt)
TW (1) TW325444B (pt)
WO (1) WO1996021701A2 (pt)
ZA (1) ZA9693B (pt)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19640834A1 (de) * 1996-10-02 1998-04-23 Pirelli Reifenwerke Verfahren zum Aufdrucken von Kennzeichnungen auf Gummiartikel, insbesondere Reifen
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
DE102007031121B3 (de) * 2007-06-29 2008-09-25 Schäfer, Konstanze, Dr. Verfahren zur Fixierung von Digitalbildern in Kunststoffen und fixiertes Digitalbild
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
FR2918906A1 (fr) * 2007-07-20 2009-01-23 Fed Mogul Systems Prot Group S Procede d'application d'un elastomere sur une gaine.
US7553854B2 (en) 2006-04-19 2009-06-30 Novartis Vaccines And Diagnostics, Inc. 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016020864A1 (en) 2014-08-06 2016-02-11 Novartis Ag Protein kinase c inhibitors and methods of their use
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019152642A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004156668A (ja) * 2002-11-05 2004-06-03 Toyox Co Ltd シリコーンホース
CN110781453B (zh) * 2019-09-23 2023-11-24 太原理工大学 一种基于复杂理论作战网络脆弱边识别方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1771843A1 (de) * 1968-06-25 1972-02-10 Tallin Politekhn I Sssr Druckfarbe
GB1295634A (pt) * 1968-11-26 1972-11-08
WO1992015649A1 (en) * 1991-03-06 1992-09-17 Sun Chemical Corporation Low rub printing ink

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0392388A (ja) * 1989-09-05 1991-04-17 Ricoh Co Ltd 感熱転写記録媒体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1771843A1 (de) * 1968-06-25 1972-02-10 Tallin Politekhn I Sssr Druckfarbe
GB1295634A (pt) * 1968-11-26 1972-11-08
WO1992015649A1 (en) * 1991-03-06 1992-09-17 Sun Chemical Corporation Low rub printing ink

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9122 Derwent Publications Ltd., London, GB; AN 91158748 XP002005498 & JP,A,03 092 388 (RICOH) , 17 April 1991 *

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19640834C2 (de) * 1996-10-02 1998-09-10 Pirelli Reifenwerke Verfahren zum Aufdrucken von Kennzeichnungen auf einen Gummiartikel, insbesondere Reifen, sowie der durch das Verfahren hergestellte Gummiartikel
DE19640834A1 (de) * 1996-10-02 1998-04-23 Pirelli Reifenwerke Verfahren zum Aufdrucken von Kennzeichnungen auf Gummiartikel, insbesondere Reifen
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
US7553854B2 (en) 2006-04-19 2009-06-30 Novartis Vaccines And Diagnostics, Inc. 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US8173689B2 (en) 2006-04-19 2012-05-08 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US8710048B2 (en) 2006-04-19 2014-04-29 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2805945A1 (en) 2007-01-10 2014-11-26 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
EP3103791A1 (en) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009003727A2 (de) 2007-06-29 2009-01-08 Schaefer Konstanze Verfahren zur fixierung von bildern in kunststoffen, haftschicht und fixiertes bild
US8414978B2 (en) 2007-06-29 2013-04-09 Coyando Gmbh Method for fixing images in plastics, adhesive layer, and fixed image
DE102007031121B3 (de) * 2007-06-29 2008-09-25 Schäfer, Konstanze, Dr. Verfahren zur Fixierung von Digitalbildern in Kunststoffen und fixiertes Digitalbild
DE102008030991A1 (de) 2007-06-29 2009-01-15 Schäfer, Konstanze, Dr. Verfahren zur Fixierung von Bildern in Kunststoffen, Haftschicht und fixiertes Bild
US8771817B2 (en) 2007-07-20 2014-07-08 Federal Mogul Systems Protection Method for applying an elastomer on a sheath
FR2918906A1 (fr) * 2007-07-20 2009-01-23 Fed Mogul Systems Prot Group S Procede d'application d'un elastomere sur une gaine.
WO2009030834A2 (fr) * 2007-07-20 2009-03-12 Federal Mogul Systems Protection Procede d'application d'un elastomere sur une gaine
WO2009030834A3 (fr) * 2007-07-20 2009-04-30 Fed Mogul Systems Prot Procede d'application d'un elastomere sur une gaine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016020864A1 (en) 2014-08-06 2016-02-11 Novartis Ag Protein kinase c inhibitors and methods of their use
EP3514151A1 (en) 2014-08-06 2019-07-24 Novartis AG Protein kinase c inhibitors and methods of their use
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US12098154B2 (en) 2015-03-27 2024-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11325910B2 (en) 2015-03-27 2022-05-10 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019152642A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Also Published As

Publication number Publication date
IL116690A0 (en) 1996-05-14
EA000164B1 (ru) 1998-10-29
CA2211017A1 (en) 1996-07-18
TW325444B (en) 1998-01-21
EP0802953A2 (en) 1997-10-29
CN1176652A (zh) 1998-03-18
AU4694996A (en) 1996-07-31
WO1996021701A3 (en) 1996-09-12
JPH11501337A (ja) 1999-02-02
EA199700099A1 (ru) 1997-12-30
IL116690A (en) 1999-03-12
MX9705033A (es) 1998-07-31
AR000644A1 (es) 1997-07-10
ZA9693B (en) 1996-08-29
AU703440B2 (en) 1999-03-25
BR9606896A (pt) 1997-10-21

Similar Documents

Publication Publication Date Title
AU703440B2 (en) Wear resistant image printing on latex surfaces
US7423002B2 (en) Method of neutralizing a stain on a surface
CN104837637B (zh) 用于数字印刷的织物预处理物
CA2724229C (en) Method of affixing a design to a surface
US5854306A (en) Wear resistant image printing on latex surfaces
KR20140016424A (ko) 부직 기질용 철판 인쇄 및 그라비어 인쇄 잉크
US20100154146A1 (en) Carpet decor and setting solution compositions
US8759442B2 (en) Water based printing inks for nonwoven substrates
US8846154B2 (en) Carpet décor and setting solution compositions
KR20100093067A (ko) 부직 기재용 플렉소그래픽 및 그라비어 인쇄 잉크
US3684545A (en) Thermosetting dry transfer
EP2044226B1 (en) Leather-surface repair-composition and the method for surface repair of leather surfaces
US3086873A (en) Silk screen printing ink
MXPA97005033A (en) Printing of images, resistant to wear, on surfaces of the
WO2006129604A1 (ja) 昇華転写プリント塗装皮革製品及びその製造方法
GB2220008A (en) Transfer printing with sublimatic dyes
JPH08155052A (ja) 絵付ゴルフボール及びゴルフボール絵付用転写箔
SU1219625A1 (ru) Состав дл покрытий
KR100206421B1 (ko) 착색용 조성물 및 이를 이용하여 형성된 착색층을 갖는 스탱핑 호일
GB1585367A (en) Copolyamides and their use for finishing leather and leather substitutes
JPS62164775A (ja) 水なし平版用陶器転写用ワニス組成物
GB2469908A (en) Transfer composition comprising isobutyrate and acrylic
TH21535A (th) ภาพที่พิมพ์บนผิวลาเทกซ์ที่คงทนต่อการสึกหรอ

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192238.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2211017

Country of ref document: CA

Ref document number: 2211017

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996902610

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005033

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1996 521749

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 08875414

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 199700099

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1996902610

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996902610

Country of ref document: EP